Advertisement

Expert Point of View: Guru Subramanian Guru Murthy


Advertisement
Get Permission

Invited discussant Guru Subramanian Guru Murthy, MD, MS, of the Medical College of Wisconsin, Milwaukee, commented on the study of aspacytarabine in the first-line therapy for patients with acute myeloid leukemia (AML) unfit for standard chemotherapy. “This study elegantly highlights there is still a role for chemotherapy in the management of AML, even in the era of targeted agents.”

Guru Subramanian Guru Murthy, MD, MS

Guru Subramanian Guru Murthy, MD, MS

Dr. Murthy continued: “An attractive aspect of this agent is the fixed duration of therapy compared with other agents, such as hypomethylating agents, venetoclax, and IDH1/2 inhibitors. Using these agents continuously until disease progression can result in treatment-related and financial toxicities for patients.” 

DISCLOSURE: Dr. Murthy has received honoraria from Cardinal Health and served as a consultant or advisor to Cancer Expert New and Techspert.

 


Related Articles

Study Finds Cytarabine Prodrug Active and Safe in Older Compromised Patients With AML

Aspacytarabine, a cytarabine prodrug, was reported to be safe and effective as first-line therapy for patients with acute myeloid leukemia (AML) who were unfit for intensive induction chemotherapy, according to the results of a phase II study presented during the 2021 ASCO Annual Meeting.1 The...

Advertisement

Advertisement



Advertisement